NCT03011814 is a Phase 1, PHASE2 clinical trial of Durvalumab in Folliculotropic Mycosis Fungoides, sponsored by City of Hope Medical Center.

Who is sponsoring NCT03011814?

NCT03011814 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT03011814?

Interventions in NCT03011814: Durvalumab, Laboratory Biomarker Analysis, Lenalidomide.

What condition does NCT03011814 study?

NCT03011814 studies Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma.

Is NCT03011814 still recruiting?

NCT03011814 is currently active, enrolled. Last updated 18 September 2025.

Last reviewed 2025-09-18 · How we verify

NCT03011814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Active, enrolled Phase 1, PHASE2 Last updated 18 September 2025

What this trial tests

Phase 1, PHASE2 trial testing Durvalumab in Folliculotropic Mycosis Fungoides in 38 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 March 2017

Primary endpoint
23 June 2026

30 August 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	8 March 2017
Primary completion	23 June 2026
Estimated completion	30 August 2026
Sites	4 locations across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Folliculotropic Mycosis Fungoides — all drugs for Folliculotropic Mycosis Fungoides →
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma — all drugs for Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma →
Recurrent Mycosis Fungoides — all drugs for Recurrent Mycosis Fungoides →
Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma — all drugs for Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Folliculotropic Mycosis Fungoides or Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Merryman RW, Armand P, Wright KT, Rodig SJ. · · 2017 · cited 87× · PMID 29296917 · DOI 10.1182/bloodadvances.2017012534
Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y, Li X, Luan Y, Luo J, et al · · 2024 · cited 34× · PMID 38178117 · DOI 10.1186/s12943-023-01904-w
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma.
Scarisbrick JJ, Bagot M, Ortiz-Romero PL. · · 2021 · cited 29× · PMID 33095448 · DOI 10.1111/bjh.17117
Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E, Ruan J. · · 2020 · cited 29× · PMID 32448357 · DOI 10.1186/s13045-020-00889-z
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.
Roccuzzo G, Giordano S, Fava P, Pileri A, et al · · 2021 · cited 24× · PMID 34485162 · DOI 10.3389/fonc.2021.733770
New developments in immunotherapy for lymphoma.
Heyman B, Yang Y. · · 2018 · cited 19× · PMID 30197788 · DOI 10.20892/j.issn.2095-3941.2018.0037
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.
Chen X, Wu W, Wei W, Zou L. · · 2022 · cited 18× · PMID 35559250 · DOI 10.3389/fphar.2022.869488

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Folliculotropic Mycosis Fungoides

Currently open trials in the same condition.

NCT04930653 — Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma · Phase 2 · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03011814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 18 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03011814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing